In a recent episode of the ‘Bell2Bell Podcast’ hosted by Stuart Smith, Astiva Health was spotlighted as a significant player in the Medicare Advantage Prescription Drug (“MAPD”) sector. The episode featured an exclusive interview with Astiva Health’s Co-Founder and CEO, Dr. Tri Nguyen, a renowned expert in internal medicine and cardiology.

Listen to the full interview to hear Dr. Nguyen discuss Astiva Health’s journey since its inception in 2020 and its expansion plans. He shared insightful details about the company’s expansion to Los Angeles, San Bernardino, and Riverside from January 1, 2024, marking a pivotal phase in transforming healthcare delivery.

One key highlight from the podcast was Astiva Health surpassing the 10,000-member milestone. Dr. Nguyen attributed this success to the company’s philosophy, which emphasizes loving life at any age. This principle is central to Astiva’s commitment to ensuring life is lived with fulfillment.

Astiva Health’s approach goes beyond providing medical care and prescription drugs. As Dr. Nguyen explains in the interview, it includes offering rich supplemental benefits to engage enrollees in a meaningful, healthy life. He emphasized the importance of patient involvement in successful medical outcomes, a cornerstone of Astiva Health’s strategy.

Looking forward in the podcast discussion, Dr. Nguyen outlined Astiva Health’s operational goals for 2024, including an ambitious plan to list its common shares on the NASDAQ Global Select. This strategic move aligns with Astiva Health’s broader goals of expanding its impact.

The vision for Astiva Health, as Dr. Nguyen shares on the Bell2Bell Podcast, is to redefine healthcare accessibility and quality. He envisions Astiva Health as a comprehensive healthcare provider for all who can benefit from it, highlighting potential growth and service expansion.

The interview concluded with Dr. Nguyen thanking Stuart Smith for the opportunity to discuss Astiva Health’s journey and future plans. For more information about Astiva Health, listeners are directed to the company’s website.

Catch the full depth of this engaging conversation with Dr. Tri Nguyen on the Bell2Bell Podcast, offering listeners a deeper understanding of Astiva Health’s mission, achievements, and future aspirations in the healthcare sector.

For more information, visit the company’s website at www.AstivaHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva

• The U.S. Securities and Exchange Commission recently won a judgment that furthers its efforts to bring crypto-based transactions under its purview, seen as enhancing the sense of security needed for larger public acceptance of the digital sector
• Many investors have taken an interest in the heady accomplishments of the digital asset sector but have been reluctant to get involved due to uncertainties or a simple wariness of having to become tech savvy
• Utah-based Diamond Lake Minerals Inc. is positioning itself as a bridge-builder that helps traditional investors step effortlessly into the digital asset sector with expectations of government-regulated stability
• DLMI’s model presents digital security token offerings as an integral element of its numerous industry-agnostic subsidiaries that have their own investor appeal

Multi-strategy operating company Diamond Lake Minerals (OTC: DLMI) is helping investors navigate the perceived complexities of adding digital assets to their portfolios by providing a more safe and simple gateway. Security tokens, registered with the U.S. Securities and Exchange Commission (“SEC”), are embedded in Diamond Lake’s subsidiaries to form a traditional investment opportunity that is also imbued with digital asset elements.

A recent federal court ruling sustaining the SEC’s continued efforts to bring more crypto-based transactions under its purview, further demonstrates the importance of the legal landscape surrounding the regulation of digital assets (https://ibn.fm/tm7UZ). DLMI’s determination to use only SEC-registered security tokens as the digital offering of its industry-agnostic subsidiaries reflects the company’s emphasis on compliance with securities laws.

“The current philosophy and model is not tokenizing the shares, but it’s actually tokenizing business units within our subsidiaries. So there’ll be an attachment to some revenue-generating mechanism within the subsidiaries that we would go out to the public markets with … and offer participation in those businesses to a global audience,” DLMI CEO Brian J. Esposito said during a recent interview with the Cryptonized webcast (https://ibn.fm/L1QHd). Diamond Lake is making its security token offerings (“STOs”) available through the SEC-regulated security token exchange INX (https://ibn.fm/e9X5l).

“As a supporter and believer and shareholder in DLMI, I want this to be a security that I never want to get rid of … and it’s also a security or a security token that I hold that pays me and my shareholders a dividend or a yield or a revenue share of some sort,” Esposito said. “In theory, you should have a Berkshire-Hathaway class A stock on your hands. … With the idea of what does the future of capitalization look like and what does the future of a global investor look like.”

Esposito said the company is trying to position its offerings as a “missing link” that will bring traditional investors over to the digital environment as they become involved with the company’s subsidiaries, which include sectors ranging from entertainment to healthcare. “You’ve got to future-proof anything. You’ve got to adapt or die. If you don’t, you die — that’s the reality,” he said.

For more information, visit the company’s website at www.DiamondLakeMinerals.com or LinkedIn page at www.LinkedIn.com/company/Diamond-Lake-Minerals/.

In addition, for information on the company’s security token SEC regulated exchange partner INX, and the development of the INX Way, visit https://www.inx.co/inx-ebook/. This free security token bible, written with the SEC on the rollout of security tokens and the future of digital assets, will greatly deepen your understanding of security tokens.

NOTE TO INVESTORS: The latest news and updates relating to DLMI are available in the company’s newsroom at https://ibn.fm/DLMI

• A recent study shows that medical cannabis treatment may be associated with improvements in health-related quality of life
• Study data indicated that chronic noncancer pain was the most common indication for treatment, followed by cancer pain, insomnia and anxiety
• MedCana is building the technology, laboratories, growing facilities and scientific teams needed to provide premium pharmaceutical-grade cannabis extracts to the world

Cannabis, long shrouded in controversy, is stepping into the limelight of scientific inquiry, revealing a complex tapestry of potential benefits. Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ), a global infrastructure and holding company in the cannabis industry, is paying close attention to growing data showing the power of the natural substance.

One recent study, conducted by postdoctoral research fellow Thomas Arkell, a PhD at Swinburne University of Technology in Melbourne, Australia, suggests that medical cannabis treatment may be associated with improvements in health-related quality of life among patients with a range of health conditions (https://ibn.fm/DUJBL). The results of the study were published earlier this year by JAMA Network Open.

“The use of cannabis as a medicine is becoming increasingly prevalent,” the report stated. “Given the diverse range of conditions being treated with medical cannabis, as well as the vast array of products and dose forms available, clinical evidence incorporating patient-reported outcomes may help determine safety and efficacy.” According to the report, this case series study was conducted at a network of specialist medical clinics and included patients who received treatment for any indication between December 2018 and May 2022.

Results of the study, which included 3,148 patients, were noteworthy. Study data indicated that chronic noncancer pain was the most common indication for treatment, followed by cancer pain, insomnia and anxiety. “After commencing treatment with medical cannabis, patients reported significant improvements relative to baseline on all eight domains of the SF-36 (the 36-item short form health survey questionnaire), and these improvements were mostly sustained over time,” JAMA reported. After controlling for potential confounders in a regression model, treatment with medical cannabis indicated marked improvement.

This is just one of innumerable studies focused on cannabis. Recently, NORML, a nonprofit organization that represents the interests of the tens of millions of Americans who use marijuana responsibly, reported that there are more than 36,000 peer-reviewed papers in the scientific literature referencing the cannabis plant and its cannabinoids, according to a keyword search on the search engine PubMed Central, the U.S. government repository for peer-reviewed scientific research (https://ibn.fm/cj9nJ).

“In recent years, this volume of research has grown exponentially, with more than 20,000 papers published just in the past decade,” the report noted. “Much of this more recent research has been dedicated to exploring and verifying cannabis’ therapeutic activities in various patient populations – including in FDA-approved gold-standard clinical trials. A summary of this clinical trial data concluded: ‘Evidence is accumulating that cannabinoids may be useful medicine for certain indications. . . . The classification of marijuana as a Schedule I drug as well as the continuing controversy as to whether or not cannabis is of medical value are obstacles to medical progress in this area. Based on evidence currently available, the Schedule I classification is not tenable; it is not accurate that cannabis has no medical value, or that information on safety is lacking.’”

This is positive news for MedCana, which has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. In addition, the company recently rounded out its portfolio of holdings with the acquisition of an irrigation and greenhouse technology company.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams needed to provide premium pharmaceutical-grade cannabis extracts to the world.

For more information, visit the company’s website at www.MedCana.net.

NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://ibn.fm/SFWJ

• GEMXX recently presented at the Sequire Investor Summit 2024, showing how their dgreater control of the mining value chain represents a significant competitive advantage
• The company shared its knowledge and expertise in all stages of its production, including gold mining, gemstone (Ammolite) production, jewelry manufacturing, and global distribution
• GEMXX continues to control all stages of its production, which enables it to manage its mining value chain and support its mine-to-market strategy
• According to a McKinsey report, mining companies that manage their value chain well can establish a significant source of competitive advantage and value creation

GEMXX (OTC: GEMZ), a company that focuses on producing gold, gemstone, and jewelry from its own land resources, production facilities, and operating assets, recently presented at the Sequire Investor Summit 2024 held in Puerto Rico (https://ibn.fm/V33Tw). In the presentation, the company shared its mine-to-market capabilities, covering all stages of its production, including gold mining, gemstone (Ammolite) production, jewelry manufacturing, and global distribution.

With the company controlling all of these stages as part of its strategy to support its mine-to-market business model, GEMXX has established a significant source of competitive advantage and value creation. As a McKinsey report details: “The mining value chain – which includes everything from extracting raw material to delivering products to consumers – is the backbone of the industry. Companies that manage their value chain well can establish a significant source of competitive advantage and value creation. By contrast, those that neglect their value chain are likely to encounter bottlenecks and constraints that will limit shipped throughput and risk yield,” (https://ibn.fm/tfkUg).

On the mining front, GEMXX specializes in the mining of gold, still the world’s most sought-after commodity, and Ammolite, a rare, opal-like gemstone that is only found on the eastern slopes of the Rocky Mountains in Southern Alberta. “Currently, the company has $600 million in proven Ammolite reserves and $200 million in gold reserves,” the company says in a video published on its website (https://ibn.fm/XI8ME).

According to GEMXX, the value of Ammolite has increased by more than 300% over the past 20 years, with the demand for Ammolite gemstone products equally rising in tandem. To meet this growing demand and capitalize on the increase in value, the company, in November 2023, announced its plan to open an Ammolite mine on the south block, one of the three separate blocks in Southern Alberta, Canada, where its Ammolite resources are located. This move is expected to help GEMXX expand its existing Ammolite gemstone production (https://ibn.fm/Yocqd).

Similarly, the company has made substantial steps to increase its proven gold reserves. Last year, GEMXX completed the acquisition of a 50% equity stake in a Canadian exploration company, Crazy Horse Mining Inc., which owns a 100% interest in two gold projects in British Columbia, Canada: Snow Creek and Rosella Creek (https://ibn.fm/R57YR). GEMXX also signed a letter of intent to acquire a 50% interest in the proven Yukon Gold Project with an estimated 4 million ounces of gold (https://ibn.fm/czyVa).

Further up the value chain, GEMXX is a renowned manufacturer of Ammolite jewelry, a status that led to an exclusive Ammolite supply agreement with Canadian Ammolite Gems by Kenneth Bradley (https://ibn.fm/anHHJ). Bradley praised the company’s quality work, saying, “It is my opinion that GEMXX supplies the finest Ammolite in the world, and that is why I have selected them as the exclusive supplier for my Ammolite jewelry.”

GEMXX also has a shopping channel division that is preparing to supply $5.5 million worth of Ammolite jewelry through 2024 as part of the company’s expansion plans, according to CEO Jay Maull. As a result of the division’s operations, Maull explained, “GEMXX Ammolite products will now have an expanded on-air presence in the United States, Canada, and Australia.”

The company continues to control each stage of its production, enabling it to manage its mining value chain. This strategy, McKinsey analysts say, can establish a significant source of competitive advantage and value creation, particularly for shareholders.

Those interested in participating through Reg A financing are encouraged to visit the company’s investor page (https://ibn.fm/718tT) or contact company officials for more information (ir@gemxx.com – 702-930-1815).

For more information, visit the company’s website at www.GEMXX.com/investors.

NOTE TO INVESTORS: The latest news and updates relating to GEMZ are available in the company’s newsroom at https://ibn.fm/GEMZ

• SuperCom is an electronic monitoring solutions developer and provider that offers the PureSecurity(TM) Suite, a comprehensive range of products that include a domestic violence monitoring solution, a GPS tracking platform called PureTrack(TM), a house arrest enforcement solution, and an inmate monitoring solution
• The company holds that its advanced domestic violence monitoring solution could play a vital role for enhancing public safety measures, particularly in light of a recent cases emphasizing the critical need for effective response in domestic violence situations
• An Illinois appellate court recently upheld a $3 million jury award to the estate of the late Vanessa Taylor, who was allegedly killed by her boyfriend, after finding sufficient evidence that two officers “cared more about going home” than protecting Taylor

On June 30, 2015, about 25 hours after the Chicago Police Department (“CPD”) had responded to a domestic violence call at a West Side, Chicago, apartment, Vanessa Taylor was allegedly killed by her boyfriend, James Thomas. The death led to a wrongful death and survival action lawsuit against the City of Chicago, following which a Cook County jury found the city liable for Taylor’s death and awarded her estate $3 million, “which is believed to be a record civil judgment under the Illinois Domestic Violence Act,” according to an article in the Chicago Tribune (https://ibn.fm/Tpkau).

The jury found that Taylor’s death was caused by CPD’s breach of its duty to protect her under the Domestic Violence Act. When officers responded to the initial call, placed on June 28, they found Taylor’s boyfriend, James Thomas, in a mental health crisis that prompted them to transport him to the hospital. Once at the hospital, Thomas was given an antipsychotic sedative, administered a mental health examination by a physician, and discharged several hours later, court documents show (https://ibn.fm/rsBV3).

By the time he was discharged, however, the police officers had already left the hospital and had gone home despite the fact that, when they responded to the call earlier, Taylor had a black eye, according to court records. Furthermore, Thomas had allegedly cut the gas line in Taylor’s building and tussled with the officers, actions the court listed as charges Thomas could have faced in connection with the incident. After being discharged, Thomas returned to the West Side apartment where he committed the alleged crime.

Justices of the Illinois First District Appellate Court recently released a strongly worded opinion upholding the $3 million jury award to the estate of the victim after finding sufficient evidence that two CPD officers “cared more about going home for the day than protecting a domestic violence victim who was killed by her alleged abuser a short time later,” the article reads.

“In light of the recent appellate court decision emphasizing the critical need for effective response in domestic violence situations, SuperCom’s advanced technology solution could play a vital role in enhancing public safety measures,” wrote SuperCom (NASDAQ: SPCB) on its LinkedIn page (https://ibn.fm/3vfY3). SuperCom is a global leader in the field of electronics monitoring (“EM”). The company offers the PureSecurity(TM) Suite, a comprehensive range of products that include a domestic violence monitoring solution, a GPS tracking platform called PureTrack(TM), a house arrest enforcement solution, and an inmate monitoring solution.

“These innovative tools are designed to provide law enforcement and criminal justice agencies with real-time data and analytics, helping prevent tragic outcomes by ensuring constant monitoring and swift response in critical situations. SuperCom’s technology demonstrates a commitment to public safety and the protection of vulnerable individuals, aligning closely with the heightened need for effective and proactive measures in domestic violence cases,” SuperCom explained in the post.

SuperCom’s life-saving domestic monitoring solution is designed to monitor the movement of domestic violence aggressors, acting as a protective front line for victims. It combines several SuperCom technologies, including the PureProtect(TM) smartphone app, the PureTag ankle bracelet, and the PureMonitor software (https://ibn.fm/d5HYc).

The PureProtect app is designed for victims. It detects proximity violations and alerts the victims whenever the domestic violence perpetrators near their location. The app uses advanced zoning, proximity, alerting, and management capabilities to both enforce a safe distance between the victims and perpetrators and update the former of the latter’s whereabouts. It achieves this without violating the victims’ privacy. The app also supports the latest GPS, cellular, Wi-Fi, and Bluetooth technologies, enabling it to communicate with the aggressor-worn PureTag ankle bracelet, which beams signals that report the wearer’s exact location.

Completing the list of technologies that make up SuperCom’s domestic monitoring solution is the PureMonitor software meant for law enforcement officers. The software tracks the location of the aggressors and victims, logging all real-time and historical instances when proximity breaches occur. It also alerts law enforcement officers of breaches and has reporting and analytics capabilities.

The PureProtect electronic domestic violence monitoring solution provides all the information needed to protect victims and enforce court restrictions. Its advanced zoning and alerting capabilities make it a vital tool in helping enforce safety measures and preventing avoidable tragic outcomes like domestic violence-related deaths.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• D-Wave’s completion of the SOC 2 Type 2 audit makes it the first full-stack quantum computing provider to achieve this compliance
• The company is deeply committed to data security as customers adopt the production use of its quantum computing solutions
• Going forward, D-Wave will perform annual SOC 2 Type 2 assessments, making the latest report available to current and potential clients upon completing a nondisclosure agreement

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the world’s first commercial supplier of quantum computers, recently announced the successful completion of its SOC 2(R) Type 2 audit on December 7, 2023. This compliance verification, which evaluates a number of operational factors including processing integrity and security controls, is of growing importance, especially as D-Wave increases commercial customer adoption and production use of its quantum computing solutions. This notable achievement makes D-Wave the first full-stack quantum computing provider to achieve SOC 2 Type 2 compliance. The Type 2 compliance follows D-Wave’s successful SOC 2 Type 1 audit in March 2023 (https://ibn.fm/XDoPR).

D-Wave CEO Dr. Alan Baratz said this was a pivotal moment for quantum computing, as the company’s customers are moving full-steam ahead into enterprise-scale adoption and deployment. “SOC 2 compliance is a key part of our production leadership, as it ensures commercial-grade security measures are established and regularly reviewed,” Baratz said. “With customers increasingly incorporating and using our quantum solutions to support daily operations, this level of data protection and security is paramount.”

The completion of the audit comes at a time when business leaders are being held more accountable for how third parties handle private information and need to ensure that the services they use to process data meet federally regulated mandates around security control and the effectiveness of the controls over time. Customers seek trusted vendors that help reduce risk and meet standards like SOC 2 as they consider where to run business-critical applications.

A-LIGN, a technology-enabled security and compliance partner trusted by more than 2,500 global organizations to help mitigate cybersecurity risks, conducted D-Wave’s SOC 2 Type 2 audit. Established by the American Institute of Certified Public Accountants (“AICPA”), the SOC 2 examination was designed for organizations of any size, regardless of industry and scope, to ensure the personal assets of potential and existing clients are safe. The SOC 2 reports are recognized internationally and verify that the company’s infrastructure, software, people, data, policies, procedures, and operations have been formally reviewed.

“Congratulations to D-Wave for completing its SOC 2 audit, a widely recognized signal of trust and security,” said Steve Simmons, COO of A-LIGN. “It’s great to work with organizations like D-Wave, who understand the value of expertise in driving an efficient audit and the importance of a high-quality final report.”

The company’s relentless pursuit of practical quantum computing has resulted in its technology being used by some of the world’s most advanced enterprises, including Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, BBVA, NEC Corporation, Pattison Food Group Ltd., DENSO, and Lockheed Martin.

D-Wave owns one of the industry’s largest quantum computer intellectual property portfolios, including more than 210 issued U.S. patents. The company has published more than 225 peer-reviewed papers in leading scientific journals.

D-Wave will perform annual SOC 2 Type 2 assessments in the future, making the latest report available to current and potential clients upon completing a nondisclosure agreement.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding D-Wave’s future SOC 2 Type 2 assessments, and the availability of the related reports to current and potential customers. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including  general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of D-Wave’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on its business; the risk that the company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the company may never achieve or sustain profitability; the risk that the company is unable to secure or protect its intellectual property; volatility in the price of its securities; the risk that its securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. D-Wave undertakes no duty to update this information unless required by law.

Social media marketing professionals, executives, businesses, and enthusiasts, are invited to attend the GSMI Social Media Strategies Summit 2024 being held as a virtual event on February 28-29, 2024. This virtual event will be attended by acclaimed social media industry leaders who will share their in-depth insights for creating winning digital marketing campaigns.

SMSSummit is a coveted social media conference platform that benefits several industry verticals and businesses by targeting greater audience reach. The conference focuses on a targeted audience of decision-makers in the social media industry. Senior marketing professionals share their experience and knowledge of time-tested social media strategies. Leverage this social media summit platform for networking and connecting with senior marketers who set the trends of the industry.

The virtual event agenda includes:

• How to create short-form engaging videos that capture audience attention.
• Understand how influencer partnerships work for all types of brands.
• Learn ways to promote transparency in marketing campaigns and conduct ethical social media practices.
• Get acquainted with new strategies to keep social marketing campaigns fresh and reach unique audiences.
• Leverage the power of novel advertising ideas and get inspired to create engaging content.
• Unleash creativity and discover the best opportunities to promote brands on social media.
• Learn the best strategies and trends for marketers in 2024 and beyond.

The Summit starts with a welcome remark from the Summit Emcee. This will be followed by speaker sessions, panel discussions, networking rounds, meetings, and open discussions on the latest content planning and creation strategies. Attendees will learn how to scale the business’s efficiencies, improve marketing campaigns, and reach their business goals using holistic social media strategies.

To know more, please visit https://ibn.fm/1HbAx.

• Cyber attacks can cost corporations millions of dollars, endangering critical sensitive information, causing major operational headaches, and affecting hard-won corporate reputations
• Microsoft recently announced detection of a cyberattack that compromised the company’s corporate emails – an attack found to be launched by a Russian state-sponsored group referred to as Midnight Blizzard
• Sekur Private Data Ltd. offers consumers, businesses, corporations, and governments, Swiss-hosted solutions for secure communications and secure data management without the use of third-party cloud services

Cybersecurity attacks can cost corporations more than significant amounts of money – they can come with hidden costs like an increase in insurance premiums, operational disruption or destruction, lost value in customer relationships, and more (https://ibn.fm/oWoDG). It isn’t just small businesses that are vulnerable to attacks. In recent years, large corporations that devote significant effort in support of security are seeing just how vulnerable they can be to cyberattacks, many of which stem from hackers gaining entry through corporate emails.

Most recently, an email cyberattack was launched against Microsoft, by a group named Midnight Blizzard, a Russian state-sponsored actor also referred to as Nobelium. On January 12, Microsoft detected the attack which began in late November, compromising some of its corporate email accounts (https://ibn.fm/xwd1w). The hackers utilized a technique called a “password spray attack,” where a user uses a single common password against multiple accounts on the same application. According to reports, the hackers were targeting email accounts to obtain information about Midnight Blizzard.

For consumers, businesses, corporations, and governments looking to ward off attacks – there is a subscription option available. Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FRA: GDT0), a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure communications and secure data management, offers a suite of secure cloud-based storage, disaster recovery, document management, encrypted email, and secure communication tools that do not rely on third-party cloud services.

Sekur’s products include:

• SekurMail(R) with SekurSend/SekurReply: an encrypted email service offering a private, safe, and powerful tool to communicate with everyone within or outside the Sekur ecosystem. SekurMail protects personal information and communications from being accessed by unauthorized parties.
• SekurVPN(R): a secure, encrypted connection between client’s devices and the internet, giving safe access to the web by routing connections through the company’s wholly-owned Swiss servers. All data sent and received is hidden from prying eyes, including the client’s Internet Service Provider, potential hackers, government surveillance agencies, and more.
• SekurMessenger(R): a Swiss-hosted private and secure messaging communications app that provides secure and private chat, self-deleting chat, voice recording, and file transfer via any mobile device, tablet, or desktop computer. The app is designed to provide military-grade encryption and privacy by ensuring that only the sender and intended recipient can read the messages exchanged.

Sekur offers customers peace of mind – with all customer information remaining confidential and safely stored in Switzerland using military grade security. All data, whether physical, network-based, or encryption security, is stored in bank-approved, state-of-the-art ISO-certified data centers used by Swiss and global banks and most United Nations organizations, as well as many corporations and governmental organizations. All user data is protected by the Swiss Federal Data Protection Act and the Swiss Federal Data Protection Ordinance, which offer some of the strongest privacy protection in the world for both individuals and organizations.

Sekur’s entire suite of encrypted email, secure messaging, and internet privacy solutions were designed to be user-friendly, while providing customers with unparalleled security solutions – stopping attacks before they happen. Sekur sells its products through its websites www.Sekur.com and www.SekurSuite.com, as well as through approved distributors and telecommunications companies worldwide.

For more information, visit the company’s website at www.SekurPrivateData.com, or the company’s product site at www.Sekur.com.

NOTE TO INVESTORS: The latest news and updates relating to SWISF are available in the company’s newsroom at https://ibn.fm/SWISF

• An innovative combination of insights from physics, chemistry, materials science, and biology positions the new nanomedicine CNM-Au8(R) to address neurodegenerative disease, such as ALS, from a new angle
• The FDA has offered guidance to Clene on CNM-Au8’s application, with discussions ongoing for the possibility of accelerated approval on the basis of improved survival, biomarker, and clinical efficacy data in people living with ALS
• With plans to move forward on many fronts for the clinical development of CNM-Au8, 2024 looks bright for Clene

Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s disease, and multiple sclerosis (“MS”).

The company’s lead drug candidate is CNM-Au8, an innovative nanomedicine uniting the principles of physics, chemistry, materials science, and biology to address neurodegenerative diseases from a new angle. Clene uses catalytic boosting of energy metabolism to enable dying neurons to resist the multiple stressors associated with disease, allowing them not only to survive but also to function.

ALS is among the most aggressive neurodegenerative diseases, in which the progressive loss of motor neurons can lead to death between 2-5 years of diagnosis. Although there are now three FDA approved drugs for the treatment of ALS, there is still great need for a drug that can slow disease progression and significantly impact survival.

Benjamin Greenberg, M.D., Clene’s Head of Medical, said that, as the company continues to analyze data from its RESCUE-ALS and Healey-ALS Regimen C phase 2 clinical programs, the evidence supports that CNM-Au8(R) treatment improved survival in people living with ALS. “We are also encouraged that the recently disclosed long-term NfL biomarker decreases are consistent with delayed clinical time-to-event outcomes,” Greenberg added.

As Clene advances, it also announced long-term results from its Phase 2 VISIONARY trial in MS, demonstrating long-term benefits on visual acuity and cognition. Lead clinician and MS clinician-scientist Michael Barnett of Sydney noted the results as “unprecedented.”

The CNM-Au8 development pathway for ALS has included:

• REPAIR-MS and REPAIR PD, two Phase 2 brain imaging studies that featured oral administration of CNM-Au8 for 12 weeks
• Improvements in brain energy metabolites in participants with MS and PD
• Evidence of target engagement, using an oral therapy to change brain energy potential

RESCUE-ALS, a nine-month, Phase 2 study:

• Randomized and placebo-controlled
• Investigated CNM-Au8 for efficacy and safety in early-stage ALS participants
• Primary endpoint: electrophysiological measure for motor unit preservation
• An unanticipated discovery during the trial: stable motor unit function in bulbar-onset ALS patients early in their disease with no detectable motor unit compromise in arms and legs, resulting in underpowering of the trial for primary endpoint
• First evidence of survival benefit and slowing of clinical worsening with CNM-Au8 treatment

HEALEY-ALS Platform trial, a six-month, Phase 2 study

• CNM-Au8 selected alongside three other ALS drugs, comprising the first four regimens of the Platform trial
• Six-month Phase 2 study; Randomized and placebo-controlled
• Investigated CNM-Au8 for efficacy and safety in participants with ALS
• Primary endpoint: change in ALSFRS-R (an instrument for evaluating the functional status of patients with Amyotrophic Lateral Sclerosis, and used to monitor functional change in a patient over time)
• No drug regimen in the Healey Trial has met primary endpoint, to date
• CNM-Au8 met the secondary endpoint of survival
• Ongoing long-term analyses of CNM-Au8 show impressive survival benefit and clinical improvement
• Significant reductions in levels of key biomarker Neurofilament light (“NfL”) with CNM-Au8 treatment during both the six-month period and one-year long-term open label period; CNM-Au8 is the first ALS drug investigated in a heterogenous ALS population to reach significance on this important ALS biomarker

The company is continuing to evaluate emerging long-term data from the RESCUE and HEALEY long term extension and their expanded access protocols (“EAP”) in ALS. Clene has announced plans for its global Phase 3 trial in ALS and is opening a new NIH-funded EAP for participants with ALS who do not qualify to participate in clinical trials in 2024.

In terms of safety, the company has accrued data on over 500 years of human subject exposure to CNM-Au8 from its clinical programs and compassionate use early access programs (FDA-approved EAPs) to date, with no serious safety signals being associated with drug treatment.

During 2024, Clene will work with the U.S. FDA to consider the strength of Clene’s data, while exploring all potential pathways to commercialization, including the possibility of accelerated approval based upon a biomarker and/or survival signal. With the supportive efficacy data and additional biomarker data in the pipeline, the company believes that the development path for CNM-Au8 looks bright in 2024.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• SOBRsafe’s alcohol detection technology can improve behavioral outcomes and help save lives
• Navix Health, a leading provider of innovative behavioral healthcare support technologies, has chosen SOBRsafe as its exclusive alcohol data partner, integrating SOBRsafe’s transdermal detection solutions into Navix Hub(TM)
• SOBRsafe’s products include SOBRsafe(TM), SOBRcheck(TM), and SOBRsure(TM)

SOBRsafe (NASDAQ: SOBR), a provider of advanced transdermal alcohol detection technology, recently announced that Navix Health, a leading provider of behavioral healthcare support technologies, has chosen SOBRsafe as its exclusive alcohol data partner, integrating the company’s transdermal detection solutions into Navix Hub(TM). With the integration of SOBRsafe into Navix Hub, customers can augment current operations with touch-based alcohol monitoring, with the results flowing directly into their client records platform. The collaboration marks a significant milestone in advancing digital health and enhancing patient-centric care (https://ibn.fm/38npo).

Dave Gandini, Chairman and CEO of SOBRsafe, said the company’s goal is to empower positive outcomes. “In this, we are wholly aligned with Navix Health, and we believe the integration with Navix Hub(TM) positions both our organizations to create maximum benefit through actionable alcohol intelligence. We are excited to partner with Navix Health, and we look forward to providing value to their customers industry-wide,” Gandini added.

SOBRsafe’s alcohol detection technology can improve workplace safety and provide advanced screening and monitoring solutions for the behavioral health industry. The company has developed a patent-pending alcohol detection device called SOBRcheck(TM) to detect alcohol in humans with just a single touch of the finger. SOBRsafe’s next-generation transdermal technology detects and instantaneously reports the presence of alcohol through the user’s skin. No breath, blood, or urine samples are required – making it a hygienic alternative to traditional breathalyzers.

SOBRsafe’s technology is integrated within the company’s robust and scalable data platform, producing statistical and measurable user and business data. The company’s products include:

• SOBRsafe(TM) – The company’s patent-pending platform for non-invasive alcohol detection, with real-time reporting and historical data aggregation. SOBRsafe is a solution that has broad potential applications across all industries, but with an immediate focus in behavioral health and justice.
• SOBRcheck(TM) – The company’s stationary identification and alcohol detection product provides quick, specific, point-of-care screening. The device verifies user identity and determines the presence or absence of alcohol, providing administrators with immediate, actionable results, delivered securely.
• SOBRsure(TM) – The company’s transdermal, alcohol-detecting wearable band that provides continuous monitoring, discreetly detecting and instantaneously reporting the presence or absence of alcohol by the band wearer. SOBRsure also provides app-based alcohol detection alerts, pinpoint location tracking and band-removal notifications.

SOBRcheck and SOBRsure revenue models consist of flexible structures ensuring monthly recurring revenue. The SOBRsafe products have a powerful backend data platform, providing humane, passive and connected alcohol detection for the behavioral health and justice markets, and for licensing, integration and consumers.

The partnership between Navix Health and SOBRsafe combines expertise to offer comprehensive digital health solutions to address the evolving needs of patients, healthcare providers and stakeholders in the healthcare industry. By integrating SOBRsafe’s advanced alcohol monitoring technology with Navix Health’s robust EMR, both companies aim to enhance patient care, increase compliance and promote better health outcomes.

For more information, visit the company’s website at www.SOBRsafe.com. 

NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR